Why Is LeMaitre Vascular (LMAT) Stock Down -24.63% Today?
Key Takeaways
- LeMaitre Vascular shares plunged 24.63% on Wednesday, trading at $79.73 after closing the prior session at $105.78, erasing roughly $470 million in market capitalization.
- The primary catalyst was a double miss on Q2 2026 earnings, with EPS of $0.74 falling well short of the $0.81 consensus and revenue of $70.38 million missing the $71.47 million estimate.
- A disappointing guidance cut compounded the sell-off, as management lowered full-year 2026 revenue guidance to $276.3 million from $280 million and reduced organic growth expectations from 12% to 11%.
- Multiple analyst downgrades and price-target cuts followed the report, with Wells Fargo lowering its target to $94 and Barrington Research downgrading the stock to "market perform."
- Trading volume surged to more than 2.6 times the daily average, signaling intense institutional repositioning following the earnings disappointment.
- Investors are now watching whether supply chain headwinds, FX pressure, and cardiac allograft constraints prove temporary or signal a more durable growth slowdown.
Opening Summary
LMAT, the ticker for LeMaitre Vascular, Inc. — a Burlington, Massachusetts-based medical device company specializing in devices and implants for peripheral vascular disease — suffered one of its steepest single-day declines on record Wednesday. Shares of LMAT tumbled 24.63% to $79.73, down from Tuesday's close of $105.78, after the company's second-quarter 2026 earnings report, released after the bell on August 4, missed Wall Street expectations on both the top and bottom lines and included a downward revision to full-year guidance. The decline marked the stock's lowest level since July 2025 and its worst single-session performance in over a decade.
Q2 2026 Earnings: A Rare Miss That Shook Confidence
LeMaitre Vascular reported Q2 2026 revenue of $70.38 million, representing 9.6% year-over-year growth but falling approximately 1.5% short of the $71.47 million consensus estimate. More significantly, GAAP earnings per share came in at $0.74, a full $0.07 below the $0.81 analysts had projected — an 8.6% shortfall that rattled a market accustomed to the company's track record of consistently beating estimates. While gross margin expanded by 210 basis points to a robust 72.1% and operating income rose 26% to a record $20.4 million, the top-line miss overshadowed what was otherwise a quarter of solid operational execution.
Management attributed the revenue shortfall to three roughly equal headwinds: a strengthening U.S. dollar that compressed reported international sales, approximately $400,000 in export orders delayed by the ongoing Middle East conflict, and cardiac allograft (RestoreFlow) supply constraints that limited growth in that product category. Additionally, catheter sales declined 11% year-over-year, a function of difficult comparisons against the prior-year period when customer hoarding followed a packaging-related recall.
Guidance Cut Fuels the Sell-Off
Perhaps more damaging than the quarterly miss itself was the company's lowered outlook for the remainder of 2026. LeMaitre cut its full-year revenue guidance to a midpoint of $276.3 million, down from $280 million, implying 11% organic growth versus the previously guided 12%. Full-year EPS guidance of $2.84 to $2.94 also came in below the $3.00 consensus. For the third quarter, management projected revenue of $66.3 million to $68.3 million and EPS of $0.66 to $0.71 — both below Street expectations of $69.0 million and $0.73, respectively.
CFO Dorian LeBlanc noted on the earnings call that the three headwinds affecting Q2 — foreign exchange, Middle East export disruptions, and cardiac allograft supply constraints — are expected to persist through the second half of the year. The company also disclosed that its QuickStitch project now faces a likely clinical trial requirement from the FDA, potentially pushing the commercialization timeline from quarters to years and introducing significant additional investment requirements.
Analyst Downgrades Amplify the Downward Pressure
The post-earnings sell-off was intensified by a wave of analyst actions on Wednesday morning. Wells Fargo lowered its price target on LMAT from $104 to $94 while maintaining an "equal weight" rating. Barrington Research downgraded the stock outright from "outperform" to "market perform," signaling diminished conviction in near-term share-price appreciation. These moves followed pre-earnings downgrades from Zacks Research (strong-buy to hold) and Weiss Ratings (buy to buy-minus) in preceding weeks. The consensus analyst rating now sits at "Hold," with a wide dispersion between the remaining bulls — Citizens JMP maintains a $127 target — and the increasingly cautious majority.
Market Context and Trading Activity
The sell-off in LMAT stands in stark contrast to the broader market, where the S&P 500 pushed to record levels above 7,700 on the same day, buoyed by optimism around potential US-Iran Hormuz negotiations and strong earnings from large-cap technology companies. The healthcare sector, in fact, has been a destination for rotating capital in recent months, with the S&P 500 healthcare index up 11.2% over the trailing three months. LMAT's decline is therefore decidedly company-specific rather than sector-driven.
Trading volume exploded to over 683,000 shares, more than 2.6 times the stock's average daily volume of approximately 257,000 shares. The stock sliced through both its 50-day moving average of roughly $97 and its 200-day moving average near $100, and approached its 52-week low of $79.39 set in 2025. The breach of these key technical levels likely triggered additional algorithmic and stop-loss selling, compounding the intraday decline.
What Comes Next for LMAT
Looking ahead, investors will be closely monitoring whether the three identified headwinds — FX, Middle East export disruptions, and cardiac allograft supply — begin to ease in the second half. The company's Artegraft product line remains a bright spot, with sales surging 34% in Q2 to represent 21% of total revenue, now the company's largest product. International expansion of Artegraft, now approved in 56 countries with Canada set to launch in September, provides a long-term growth runway.
However, risks remain. The cardiac allograft supply constraints show no immediate signs of resolution, the QuickStitch regulatory path has become more uncertain, and the company's premium valuation — even after the sell-off — leaves little room for further execution missteps. With $376 million in cash and a strong balance sheet, LeMaitre retains strategic optionality, including the ability to pursue acquisitions in the $15 million to $150 million revenue range. The company's next quarterly update will be critical in determining whether this quarter's miss represents a temporary stumble or the beginning of a more sustained deceleration.
Trending AI Robots
In volatile market environments like the one currently impacting LMAT, traders increasingly turn to data-driven tools to navigate shifting conditions. Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing AI-powered trading bots, designed to adapt to evolving market dynamics across thousands of tickers. These bots span diverse strategies, timeframes, and performance metrics — from short-term momentum plays to longer-duration trend followers — and only the strongest performers under current conditions are featured. Explore the Trending AI Robots page to discover which strategies are delivering results in today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Momentum Indicator for LMAT turns positive, indicating new upward trend
LMAT saw its Momentum Indicator move above the 0 level on September 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 103 similar instances where the indicator turned positive. In 71 of the 103 cases, the stock moved higher in the following days. The odds of a move higher are at 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for LMAT just turned positive on August 28, 2026. Looking at past instances where LMAT's MACD turned positive, the stock continued to rise in 34 of 50 cases over the following month. The odds of a continued upward trend are 68%.
Following a +1.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where LMAT advanced for three days, in 232 of 341 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 70 cases where LMAT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LMAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
LMAT broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LMAT entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.480) is normal, around the industry mean (5.011). P/E Ratio (28.790) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (2.178) is also within normal values, averaging (4.456). Dividend Yield (0.012) settles around the average of (0.005) among similar stocks. P/S Ratio (7.267) is also within normal values, averaging (56.074).
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. LMAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vascular devices for vascular surgeons
Industry PharmaceuticalsOther
Advertisement